Skip to main content

Table 2 Evaluation of blood stream infections.

From: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients

Item

Group 1

(heparin)

Group 2

(TauroLockā„¢)

P value

No. of BSI events

30

25

Ā 

No. (%) of patients with at least 1 BSI

24 (27)

21 (24)

0.74

No. (%) of BSI with CoNS* or MRSEĀ§

14 (47)

3 (11)

0.004

Ā 

ā€ƒā€ƒā€ƒCoNS: 4 (13)

ā€ƒā€ƒā€ƒCoNS: 3 (11)

Ā 
Ā 

ā€ƒā€ƒā€ƒMRSE: 10 (33)

ā€ƒā€ƒā€ƒMRSE: 0 (0)

Ā 

Incidence densityā€” for All BSI events (CI95)

4.93 (3.33ā€“7.04)

3.82 (2.52ā€“5.56)

0.35

Incidence densityā€” calculated with the number of specific isolates

Ā Ā Ā 

ā€ƒā€ƒā€ƒBSI with CoNS/MRSE

2.30 (1.26ā€“3.86)

0.45 (0.09ā€“1.31)

0.004

ā€ƒā€ƒā€ƒBSI other Gram positive

0.66 (0.18ā€“1.68)

1.19 (0.52ā€“2.35)

0.32

ā€ƒā€ƒā€ƒBSI E. coli

0.66 (0.18ā€“1.68)

1.49 (0.72ā€“2.74)

0.15

ā€ƒā€ƒā€ƒBSI all Gram negative

1,97 (1.02ā€“3.44)

2.24 (1.25ā€“3.69)

0.74

  1. Group 1 = heparin (2004ā€“2005) vs. group 2 = TauroLockā„¢ (2005ā€“2006)
  2. * CoNS = coagulase-negative Staphylococci (methicillin-sensitive)
  3. Ā§MRSE = methicillin-resistant coagulase-negative Staphylococci
  4. + The percentage refers to all documented BSI in this group (100%).
  5. ā€” The ID refers to the number of events per 1000 inpatient CVAD utilization days.
  6. Ī” IQR = interquartile range, 25ā€“75. Percentile